Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial-Reference-Cited by-同舟云学术

Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial

Published:2024-07 Issue: Volume:205 Page:114103
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Rescigno Pasquale,Porta Nuria,Finneran Laura,Riisnaes Ruth,Figueiredo Ines,Carreira Suzanne,Flohr Penny,Miranda Susana,Bertan Claudia,Ferreira Ana,Crespo Mateus,Rodrigues Daniel Nava,Gurel Bora,Nobes Jenny,Crabb Simon,Malik Zafar,Ralph Christy,McGovern Ursula,Hoskin Peter,Jones Robert J.,Birtle Alison,Gale Joanna,Sankey Peter,Jain Suneil,McLaren Duncan,Chadwick Eliot,Espinasse Aude,Hall Emma,de Bono Johann

Funder

AstraZeneca plc

Prostate Cancer UK

Cancer Research UK

Prostate Cancer Foundation

Publisher

Elsevier BV

Reference27 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J Clin,2018

2. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate;Huggins;CA Cancer J Clin,1972

3. Molecular determinants of resistance to antiandrogen therapy;Chen;Nat Med,2004

4. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

5. Increased survival with enzalutamide in prostate cancer after chemotherapy;Scher;N Engl J Med,2012

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The efficacy and safety of PI3K and AKT inhibitors for patients with cancer: A systematic review and network meta-analysis;European Journal of Pharmacology;2024-11